retatrutide phase 3 results october 2025 New data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats Retatrutide Phase 3: 60% Achieved

However, a recent retrospective cohort study using a nationwide commercial administrative claims database including 6,806,046 patients with T2DM who underwent outpatient upper endoscopy from 2005 to 2021reported contrasting findings

Tirzepatide Tirzepatide, also known by the brand names Mounjaro and Zepbound, is an FDA-approved dual-action GLP-1/GIP receptor agonist made by Eli Lilly

doi: 10.1152/physrev.00034.2015

Tirzepatide and retatrutide (single molecule): A single engineered molecule that hits multiple receptors simplifies the formulation to one compound with one pharmacokinetic profile, and allows the balance of receptor activation to be tuned at the molecular-design level